Navigation Links
Questcor Reports Third Quarter Financial Results
Date:10/29/2013

areas: increased penetration of Acthar in current markets and expansion into additional on-label markets, globalization of Synacthen and Acthar, development of new indications and markets, and the appropriate deployment of cash that we believe will be generated from these activities."

"New paid prescriptions for Acthar were strong across all of our markets, totaling approximately 2,450 to 2,500 in the third quarter, about a 30% increase from a year ago," commented Steve Cartt, Chief Operating Officer of Questcor. "We continue to experience a strong early level of prescribing of Acthar in the rheumatology-related indications dermatomyositis, polymyositis, lupus and rheumatoid arthritis. There were 450 to 460 new paid Acthar prescriptions for these FDA-approved rheumatology indications during the third quarter, up about 43% from the second quarter.  Notably, in only our second full quarter of promotion to rheumatologists, rheumatology prescriptions already account for nearly a quarter of total Acthar business."

Mr. Cartt continued, "There were also 370 to 380 new paid prescriptions for NS in the quarter, up about 7% year-over-year.  NS prescriptions currently account for about one third of our Acthar business.  Particularly encouraging was the record level of Acthar prescriptions for the treatment of MS relapse, despite this being one of our more mature markets.  During the third quarter there were 1,370 to 1,400 new paid prescriptions for MS relapse patients, up about 4% year-over-year. MS relapse prescriptions currently represent between 25% and 30% of our Acthar business.  New paid prescriptions for IS were also up, reaching 225 to 230, an increase of 33% year-over-year."

"We have recently begun hiring personnel for our initial effort to educate pulmonologists about Acthar in the treatment of respiratory manifestations of symptomatic sarcoidosis, an orphan inflammatory disease with high unmet medical need for which Act
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Does your doctor ... nearly 800 doctors have recommended marijuana to the over 112,000 ... 20. But the majority of the other roughly 20,300+ active ... know very little about it – even though a poll ... adults say they have tried it. ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... , August 29, 2014 ... by Product & Services (Equipment, Reagent, Primer, Probe, ... (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) ... the global Oligonucleotide Synthesis Market is expected to ... in 2014, growing at a CAGR of 9.8% ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... 4 Shire plc ... biopharmaceutical company, today announced that the US Food and ... information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) ... CII, to include supplemental data demonstrating significant improvement in ...
... , May 4 Kaiser Permanente, committed to improving the ... require suppliers to provide environmental data for $1 billion worth ... other facilities. , , , ... Scorecard is the first of its kind in health care. It will ...
Cached Medicine Technology:FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 2FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 3FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 5FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 6FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 7FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 8Kaiser Permanente Launches Sustainability Scorecard for Medical Products 2Kaiser Permanente Launches Sustainability Scorecard for Medical Products 3
(Date:9/1/2014)... Mass., (PRWEB) September 01, 2014 BCC ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , ... $21.8 million in 2013 and is expected to reach ... grow to $471.5 million by 2019, which is equivalent ... through 2019. The receptor-mediated transport (RMT) segment is forecasted ...
(Date:9/1/2014)... 01, 2014 Registration is now open for ... and 1-Mile Race to be held on Sunday, September 21, ... Yard at Harmon Meadow in Secaucus, New Jersey. All proceeds ... national nonprofit dedicated to restoring a sense of self, restoring ... and our military families. , General registration is $30 with ...
(Date:9/1/2014)... 2014 The Outlier Series announced the ... interview content from one of the exceptional women featured ... Women Game Changers . The title of the upcoming ... Changer Jenny McClendon . McClendon is currently a full-time ... the star of WeTV show, Raising Sextuplets. , Jenny ...
(Date:9/1/2014)... Vegas, Nevada (PRWEB) September 01, 2014 ... host to over 3,000 medical professionals and 10,000 consumers ... Week is a 5-day gathering of the nation’s top ... its associated diseases or conditions. The week-long event contains ... relevant evidence-based scientific instruction available in the pain management ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 MYMOBILEUNI ... community utilizing social media marketing tools access to ... programs. MMU will utilize all tools to reach ... partner for our multiple learning channels. , MMU, ... app, and an authoring tool that applies social ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3
... Don,t Disclose Depression to Their Physicians , Many adults ... of depression to their primary care physician. In a ... one or more reasons for not talking to a ... frequently cited reason being concern the physician would recommend ...
... to reduce federal health care spending in a socially ... letter to the Congressional Joint Committee on ... "On behalf of ACP,s 132,000 members, ACP ... framework to achieve hundreds of billions of dollars in ...
... , MONDAY, Sept. 12 (HealthDay News) -- Women with ... risk of developing breast and ovarian cancers, are being diagnosed ... ,We found with some mathematical modeling about a ... Jennifer Litton, a breast medical oncologist at the University of ...
... 12, 2011 The American Society for Gastrointestinal Endoscopy ... its program specifically dedicated to promoting quality in endoscopy, ... United States. The ASGE Endoscopy Unit Recognition Program honors ... quality assurance, endoscope reprocessing and CDC infection control guidelines. ...
... BVES butts heads with colorectal cancer Once a ... to a distant site it becomes much harder to treat. ... Williams, at Vanderbilt University School of Medicine, Nashville, has now ... progression to this dangerous state, leading them to suggest that ...
... multi-disciplinary expert panel, convened by the American Dental Association ... month containing clinical recommendations that sugar-free chewing gum, lozenges ... and a prescription varnish with chlorhexidine and thymol could ... to a comprehensive cavity prevention program which includes ...
Cached Medicine News:Health News:September/October 2011 Annals of Family Medicine Tip Sheet 2Health News:September/October 2011 Annals of Family Medicine Tip Sheet 3Health News:September/October 2011 Annals of Family Medicine Tip Sheet 4Health News:September/October 2011 Annals of Family Medicine Tip Sheet 5Health News:September/October 2011 Annals of Family Medicine Tip Sheet 6Health News:September/October 2011 Annals of Family Medicine Tip Sheet 7Health News:September/October 2011 Annals of Family Medicine Tip Sheet 8Health News:Reduce health care spending in socially and fiscally responsible manner, ACP to Congress 2Health News:Women With BRCA Mutations Get Cancer Diagnosis Earlier Than Before 2Health News:Women With BRCA Mutations Get Cancer Diagnosis Earlier Than Before 3Health News:ASGE recognizes 21 endoscopy units for quality and safety 2Health News:ASGE recognizes 21 endoscopy units for quality and safety 3Health News:JCI online early table of contents: Sept. 12, 2011 2Health News:JCI online early table of contents: Sept. 12, 2011 3Health News:JCI online early table of contents: Sept. 12, 2011 4Health News:JCI online early table of contents: Sept. 12, 2011 5Health News:JCI online early table of contents: Sept. 12, 2011 6Health News:JCI online early table of contents: Sept. 12, 2011 7Health News:JCI online early table of contents: Sept. 12, 2011 8Health News:Sugar-free polyol gum, lozenges, hard candy; Nonfluoride varnishes help prevent cavities 2Health News:Sugar-free polyol gum, lozenges, hard candy; Nonfluoride varnishes help prevent cavities 3
... potent glucocorticoid produced by the human ... is bound with high affinity to ... loosely bound to albumin. Cortisol acts ... in numerous physiologic systems, including immune ...
... or somatomedin C) is a 7.6 kDa peptide ... a potent mitogen of cellular proliferation, exerting its ... the circulation, IGF-I is bound to IGF-binding proteins ... IGF-I by modulating the interaction of IGF-I with ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
Urovac bladder evacuator with adaptor...
Medicine Products: